The Global Health Body Sounds Warning Over Acute Scarcity of Weight-Loss Jabs

Under 10% of individuals eligible to benefit from weight-loss injections like Wegovy can access them, caution the World Health Organization as it publishes its initial guidance on the medications.

With in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging more widespread and fairer availability to these injectable treatments.

Per forecasts, more than two billion are projected to be obese by 2030 unless action is taken.

"The new guidance acknowledges that excess weight is a lifelong illness that can be treated with holistic and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are key hurdles to widespread access to the jabs that can assist patients in reducing considerable weight, says the body.

Weight-Loss Drug Shortage

Even in the present best projected scenario, the manufacturing of such drugs could only cover around 100 million people – fewer than 10% of the global need, according to the WHO.

The guideline calls on nations and manufacturers to widen availability, via strategies including licensing agreements.

Exclusive production rights on semaglutide – the core ingredient of a leading brand – is due to expire in multiple countries in 2026.

How Weight-Loss Drugs Operate

The injections replicate a biological compound to reduce digestion speed, curb appetite and boost satiety so individuals consume fewer calories.

People commonly begin shedding pounds after several weeks of beginning the regular doses.

Studies points to users may regain a significant portion a year later of halting the drug, as their normal appetite return.

To be carrying excess weight increases your likelihood for contracting diseases, like diabetes, heart disease, brain attack, and some cancers.

Obesity affects individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.